

# Development of first-in-class tuberous sclerosis brain disease therapeutic targeting Rheb GTPase

K-medihub/New drug development center



NEUROLOGY		Hit
Product Type	Small molecules	
Indication	Tuberous Sclerosis Complex (TSC)	
Target	Rheb (Ras homolog enriched in brain) GTPase protein	
MoA(Mechanism of Action)	Inhibition of Rheb and mTORC1 interaction	
Competitiveness	First-in-class Rheb inhibitor	
Development Stage	Hit	
Route of Administration	Oral (final goal)	

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*